Choir Singing in Aphasia Rehabilitation
Launched by UNIVERSITY OF HELSINKI · Apr 10, 2018
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
BACKGROUND: Singing is a highly stimulating and versatile activity for the brain, combining vocal-motor, auditory, linguistic, cognitive, emotional, and social brain processes, both in the left and right hemisphere. The capacity to sing is often preserved in aphasia after stroke, and singing-based methods, such as Melodic Intonation Therapy (MIT), can be effective in rehabilitating speech production in aphasics. Also emotionally and socially, singing could provide a powerful alternative channel for aphasic patients to express their emotions and interact with others, but the communal or grou...
Gender
ALL
Eligibility criteria
- The following inclusion criteria are used in patient recruiment:
- • 1. age over 18
- • 2. Finnish-speaking
- • 3. time since stroke \> 6 months
- • 4. at least minor non-fluent aphasia due to stroke (BDAE Aphasia Severity Rating scale score ≤ 4)
- • 5. no hearing deficit
- • 6. no severe cognitive impairment affecting comprehension (the patient is able to understand the purpose of the study and give an informed consent)
- • 7. no neurological / psychiatric co-morbidity or substance abuse
- • 8. ability to produce vocal sound (through singing or humming).
About University Of Helsinki
The University of Helsinki, a prestigious institution in Finland, is dedicated to advancing health sciences through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, the university engages in cutting-edge studies that aim to improve patient outcomes and contribute to the global knowledge base in medicine. Its commitment to ethical standards and rigorous methodology ensures the integrity and reliability of its clinical research initiatives, making it a key player in the development of novel therapeutic strategies and healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Helsinki, , Finland
Helsinki, , Finland
Patients applied
Trial Officials
Teppo Särkämö, PhD
Principal Investigator
University of Helsinki
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials